What is the appropriate management for a 10-year-old male with persistent nocturnal enuresis, no constipation or other urinary symptoms, and a history of bilateral orchiopexy?

Management of Nocturnal Enuresis in a 10-Year-Old Male

Begin with behavioral interventions and lifestyle modifications as first-line therapy, including regular daytime voiding schedules, fluid restriction in the evening (≤200 ml after dinner), and keeping a dry/wet night calendar; if this fails after 2-3 months, initiate desmopressin 0.2-0.4 mg oral tablets taken 1 hour before bedtime, or consider enuresis alarm therapy as an alternative first-line treatment. 1

Initial Assessment and Behavioral Management

This 10-year-old presents with monosymptomatic nocturnal enuresis (MNE) given the absence of daytime urinary symptoms or constipation. The history of bilateral orchiopexy is not directly relevant to enuresis management but should be noted.

Recommended Initial Evaluation:

• Complete a frequency-volume chart for at least 2 days measuring fluid intake and voided volumes, with notation of wet/dry nights for at least 1 week 1
• Urine dipstick to exclude glycosuria (diabetes) and proteinuria (kidney disease) 1
• Assess nocturnal urine production by weighing diapers/pull-ups to determine if nocturnal polyuria is present (>130% of expected bladder capacity for age) 1
• No routine imaging or blood work is needed for uncomplicated MNE 1

First-Line Behavioral Interventions (Grade Ib-IV Evidence):

Structured voiding schedule: The child should void at specific times - upon waking, twice during school, after school, at dinner, and immediately before sleep (not just at bedtime, but when lights go out) 1

Fluid and solute management:

• Liberal intake during morning and early afternoon
• Evening intake restricted to ≤200 ml (6 ounces) after dinner until morning 1
• This is critical for safety if desmopressin is later used

Dry/wet night calendar: Has independent therapeutic effect (Grade Ib evidence) and provides baseline for judging treatment response 1

Family education: Reassure that bedwetting is neither the child's nor parents' fault; the child should lead a normal life and know enuresis is common 1

Waking at night: Parents may wake the child to void, but this only helps that specific night and is not curative 1

Pharmacological Treatment Options

If behavioral measures fail after 2-3 months, proceed to active treatment:

Desmopressin (Grade Ia Evidence - First-Line Medication):

Desmopressin is the evidence-based pharmacological first-line therapy, with 30% achieving complete response and 40% partial response. 1

Optimal candidates for desmopressin:

• Children with nocturnal polyuria (>130% expected bladder capacity)
• Normal bladder reservoir function (maximum voided volume >70% expected capacity)
• Those who failed or cannot comply with alarm therapy 1

Dosing specifics:

• Oral tablets: 0.2-0.4 mg taken 1 hour before sleep (not bedtime - when actually going to sleep) 1
• Dose is not weight or age-dependent
• Effect is immediate if it will work
• Can be used daily or only before important nights based on family preference 1

Critical safety warning:

• Avoid nasal spray formulation - higher risk of water intoxication with hyponatremia and convulsions 1
• Polydipsia is an absolute contraindication 1
• Strict evening fluid restriction (≤200 ml) is mandatory to prevent water intoxication 1
• If using daily, implement regular short drug holidays to assess ongoing need 1

Enuresis Alarm Therapy (Alternative First-Line):

Alarm therapy achieves 50-70% success rates and is considered first-line non-pharmacological treatment, though it requires high family motivation and compliance 2, 3. This may be preferred if:

• Family prefers non-medication approach
• Nocturnal polyuria is not the primary mechanism
• Long-term cure rather than symptom control is the goal

Treatment-Resistant Cases

If standard desmopressin or alarm therapy fails:

Anticholinergics (Second-Line):

Only indicated after standard treatment failure and require:

1. Completion of frequency-volume chart
2. Uroflowmetry with post-void residual measurement
3. Exclusion of constipation 1

Options: Tolterodine 2 mg, oxybutynin 5 mg, or propiverine 0.4 mg/kg at bedtime (may need doubling) 1

Often requires combination with desmopressin - approximately 40% of treatment-resistant children respond 1

Monitor for: Constipation (most common side effect), post-void residual causing UTIs, mood changes (less common with tolterodine/propiverine than oxybutynin) 1

Imipramine (Third-Line Only):

Reserved for tertiary care facilities due to cardiotoxicity risk; 50% response rate but significant safety concerns including potential fatal overdose 1

Common Pitfalls to Avoid

1. Starting desmopressin without establishing fluid restriction - risks life-threatening hyponatremia 1
2. Using nasal spray desmopressin - removed from indication in many countries due to water intoxication risk 1
3. Failing to complete frequency-volume chart - misses diagnostic information and prognostic indicators 1
4. Not addressing constipation if present - significantly reduces treatment success even though this patient reportedly has none 1
5. Jumping to anticholinergics without proper evaluation - requires uroflowmetry and post-void residual assessment first 1

Practical Algorithm for This Patient

1. Weeks 1-2: Implement behavioral measures (voiding schedule, fluid restriction, calendar), complete frequency-volume chart
2. Weeks 3-12: Continue behavioral interventions, assess response
3. If inadequate response: Initiate desmopressin 0.2-0.4 mg oral tablets 1 hour before sleep OR enuresis alarm based on family preference and nocturnal polyuria assessment
4. If partial response to desmopressin: Consider dose adjustment or regular drug holidays to assess ongoing need
5. If treatment failure: Refer for uroflowmetry/post-void residual, consider anticholinergic addition or combination therapy

The prognosis is generally favorable - even without treatment, spontaneous resolution occurs at approximately 14% per year, though 3% remain enuretic into adulthood 3. Active treatment is justified given the significant psychosocial impact on quality of life 1, 4.